slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Memantine in Vascular Dementia: Subgroup Analyses PowerPoint Presentation
Download Presentation
Memantine in Vascular Dementia: Subgroup Analyses

Loading in 2 Seconds...

play fullscreen
1 / 6

Memantine in Vascular Dementia: Subgroup Analyses - PowerPoint PPT Presentation


  • 95 Views
  • Uploaded on

Memantine in Vascular Dementia Möbius H.J. and Stöffler A. International Psychogeriatrics 2003, 15 Suppl 1: 207-213. Memantine in Vascular Dementia: Subgroup Analyses. Analyses based on studies in patients with mild to moderate vascular dementia: Orgogozo et al. (2002) (MMM300)

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Memantine in Vascular Dementia: Subgroup Analyses' - qamar


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Memantine in Vascular DementiaMöbius H.J. and Stöffler A.International Psychogeriatrics 2003, 15 Suppl 1: 207-213

memantine in vascular dementia subgroup analyses
Memantine in Vascular Dementia: Subgroup Analyses

Analyses based on studies in patients with mild to moderate vascular dementia:

    • Orgogozo et al. (2002) (MMM300)
    • Wilcock et al. (2002) (MMM500)
  • ADAS-cog analysis by severity at baseline:
    • MMSE 20-22
    • MMSE 15-19
    • MMSE 10-14
  • ADAS-cog analysis by neuroradiological findings at baseline:
    • Macrolesions, “Large Vessel Disease”
    • No macrolesions, “Small Vessel Disease”

Möbius and Stöffler, Int Psychogeriatr 2003

patients with large vessel disease hardly show cognitive decline

ADAS-cog mean change from baseline ITT, LOCF, N = 214

-2

-1

0

1

2

3

Pooled data

Improvement

ADAS-cog score difference

 Memantine (20 mg/day)

 Placebo

Worsening

0

12

28

Week

Patients with “Large Vessel Disease” Hardly Show Cognitive Decline

Möbius and Stöffler, Int Psychogeriatr 2003

significant benefit of memantine in patients with small vessel disease

ADAS-cog mean change from baseline ITT, LOCF, N = 553

-2

-1

0

1

2

3

Pooled data

*

Improvement

 Memantine (20 mg/day)

 Placebo

Worsening

0

12

28

Week

*p = 0.002 versus placebo

Significant Benefit of Memantine in Patients with “Small Vessel Disease”

ADAS-cog score difference

Möbius and Stöffler, Int Psychogeriatr 2003

largest benefit of memantine in more severely demented patients
Largest Benefit of Memantine in More Severely Demented Patients

Mean ADAS-cog change from baseline ITT, LOCF

-2

-1

0

1

2

3

4

5

-1.38

-0.80

Improvement

0.32

0.50

0.53

0.99

0.94

0.95

ADAS-cog score difference

1.35

 Memantine (20 mg/day)

 Placebo

2.43

Worsening

4.12

4.40

20-22 15-19 10-14 20-22 15-19 10-14

MMSE at baseline

MMM500

MMM300

Möbius and Stöffler, Int Psychogeriatr 2003

summary
Summary

The strongest effect of memantine on cognition was shown

  • in the moderately demented patient population (MMSE < 15 at baseline)

and

  • in the subgroup of patients with “small vessel disease” (no macrolesions in CT/MRI)

Möbius and Stöffler, Int Psychogeriatr 2003